ValuEngine Downgrades Viveve Medical (VIVE) to Strong Sell
ValuEngine downgraded shares of Viveve Medical (NASDAQ:VIVE) from a sell rating to a strong sell rating in a report issued on Thursday morning.
Several other equities analysts have also recently issued reports on VIVE. Mizuho restated a buy rating and issued a $10.00 price target on shares of Viveve Medical in a research report on Thursday, February 1st. Ladenburg Thalmann Financial Services restated a buy rating on shares of Viveve Medical in a research report on Thursday, January 4th. Finally, Northland Securities assumed coverage on shares of Viveve Medical in a research report on Friday, January 5th. They issued an outperform rating and a $8.00 price target for the company. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $10.00.
Viveve Medical (NASDAQ VIVE) opened at $4.24 on Thursday. The company has a debt-to-equity ratio of 2.72, a current ratio of 3.89 and a quick ratio of 3.63. Viveve Medical has a 12-month low of $3.30 and a 12-month high of $11.16. The stock has a market cap of $131.10, a P/E ratio of -1.96 and a beta of -0.79.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.